November 23, 2016 - By Peter Kolinski
Eric Desparbes, the well informed person, who is the present SVP and CFO of Innoviva Inc made a sale of approx. 1,800 shares of the firm worth roughly $19,602 U.S Dollars based on a stock price of 10.9 U.S Dollars per share. Eric Desparbes owns 0.21% of the -company’s market cap or 231,327 shares.
The stock decreased 0.09% or $0.01 during the last trading session, hitting $10.91. About 621,247 shares traded hands. Innoviva Inc (NASDAQ:INVA) has declined 20.64% since April 20, 2016 and is downtrending. It has underperformed by 25.20% the S&P500.
Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The company has a market cap of $1.19 billion. The Firm is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It has a 34.4 P/E ratio. The Company’s portfolio focuses on the respiratory assets partnered with Glaxo Group Limited , including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
According to Zacks Investment Research, “Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company’s portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.”
More recent Innoviva Inc (NASDAQ:INVA) news were published by: Streetinsider.com which released: “Form 3 Innoviva, Inc. For: Nov 18 Filed by: Duncan Barbara Gayle” on November 21, 2016. Also Streetinsider.com published the news titled: “GlaxoSmithKline (GSK), Innoviva (INVA) Announce Filing of FF/UMEC/VI ..” on November 21, 2016. Seekingalpha.com‘s news article titled: “Innoviva: On Track To Buy Back The Whole Company” with publication date: February 04, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.